{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:51:25Z","timestamp":1790700685518,"version":"4.1.0"},"reference-count":254,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Pancreatic cancer is a highly aggressive malignancy that features high recurrence rates and the poorest prognosis of all solid cancers. The urokinase plasminogen activation system (uPAS) is strongly implicated in the pathophysiology and clinical outcomes of patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all pancreatic cancers. Overexpression of the urokinase-type plasminogen activator (uPA) or its cell surface receptor uPAR is a key step in the acquisition of a metastatic phenotype via multiple mechanisms, including the increased activation of cell surface localised plasminogen which generates the serine protease plasmin. This triggers multiple downstream processes that promote tumour cell migration and invasion. Increasing clinical evidence shows that the overexpression of uPA, uPAR, or of both is strongly associated with worse clinicopathological features and poor prognosis in PDAC patients. This review provides an overview of the current understanding of the uPAS in the pathogenesis and progression of pancreatic cancer, with a focus on PDAC, and summarises the substantial body of evidence that supports the role of uPAS components, including plasminogen receptors, in this disease. The review further outlines the clinical utility of uPAS components as prospective diagnostic and prognostic biomarkers for PDAC, as well as a rationale for the development of novel uPAS-targeted therapeutics.<\/jats:p>","DOI":"10.3390\/biom12020152","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T08:09:20Z","timestamp":1642493360000},"page":"152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-2115","authenticated-orcid":false,"given":"Ashna A.","family":"Kumar","sequence":"first","affiliation":[{"name":"Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia"},{"name":"School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-3371","authenticated-orcid":false,"given":"Benjamin J.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia"},{"name":"School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-9645","authenticated-orcid":false,"given":"Marie","family":"Ranson","sequence":"additional","affiliation":[{"name":"Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia"},{"name":"School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccell.2016.12.006","article-title":"Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer","volume":"31","author":"Halbrook","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1120-9","article-title":"Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: A large, international population-based study","volume":"16","author":"Huang","year":"2018","journal-title":"BMC Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: Current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/1319-3767.93815","article-title":"Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy","volume":"18","author":"Breidert","year":"2012","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002689900215","article-title":"Recurrence after resection for ductal adenocarcinoma of the pancreas","volume":"21","author":"Sperti","year":"1997","journal-title":"World J. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e183617","DOI":"10.1001\/jamasurg.2018.3617","article-title":"International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer","volume":"153","author":"Kasumova","year":"2018","journal-title":"JAMA Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.2010.226092","article-title":"Stromal biology and therapy in pancreatic cancer","volume":"60","author":"Neesse","year":"2011","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1586\/era.10.148","article-title":"Challenges of drug resistance in the management of pancreatic cancer","volume":"10","author":"Sheikh","year":"2010","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","article-title":"Molecular and cellular mechanisms of chemoresistance in pancreatic cancer","volume":"68","author":"Adamska","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Amrutkar, M., and Gladhaug, I.P. (2017). Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers, 9.","DOI":"10.3390\/cancers9110157"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X13478680","article-title":"Pancreatic cancer: Why is it so hard to treat?","volume":"6","author":"Oberstein","year":"2013","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.18632\/oncotarget.2972","article-title":"Molecular landscape of pancreatic cancer: Implications for current clinical trials","volume":"6","author":"Heestand","year":"2015","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.18632\/oncotarget.27727","article-title":"A comprehensive analysis of clinical trials in pancreatic cancer: What is coming down the pike?","volume":"11","author":"Katayama","year":"2020","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2009.89","article-title":"Pancreatic cancer: Molecular pathogenesis and new therapeutic targets","volume":"6","author":"Wong","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","article-title":"The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data","volume":"10","author":"Bengtsson","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1245\/s10434-011-1900-3","article-title":"Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades","volume":"19","author":"Winter","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","first-page":"613","article-title":"Proteases as prognostic markers in cancer","volume":"2","author":"Duffy","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0009-8981(99)00224-7","article-title":"Unraveling the role of proteases in cancer","volume":"291","author":"Koblinski","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10555-019-09811-7","article-title":"Cell surface\u2013anchored serine proteases in cancer progression and metastasis","volume":"38","author":"Martin","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fonc.2020.00397","article-title":"Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression","volume":"10","author":"Brassart","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Procacci, P., Moscheni, C., Sartori, P., Sommariva, M., and Gagliano, N. (2018). Tumor\u2013Stroma Cross-Talk in Human Pancreatic Ductal Adenocarcinoma: A Focus on the Effect of the Extracellular Matrix on Tumor Cell Phenotype and Invasive Potential. Cells, 7.","DOI":"10.3390\/cells7100158"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI115405","article-title":"The plasminogen activator\/plasmin system","volume":"88","author":"Vassalli","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_29","first-page":"1079","article-title":"Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer","volume":"1","author":"Peters","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","article-title":"Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients","volume":"94","author":"Look","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/0008-5472.CAN-03-1242","article-title":"Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin","volume":"64","author":"Nielsen","year":"2004","journal-title":"Cancer Res."},{"key":"ref_32","first-page":"1","article-title":"Serum level of Urokinase Plasminogen Activator (uPA) Correlates with the Survival of Patients with Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"5","author":"Winter","year":"2015","journal-title":"Pancreat Disord Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/bjc.1997.63","article-title":"Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma","volume":"75","author":"Cantero","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1541-7786.MCR-10-0452","article-title":"Suppression of the uPAR\u2013uPA System Retards Angiogenesis, Invasion, andIn VivoTumor Development in Pancreatic Cancer Cells","volume":"9","author":"Gorantla","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.2353\/ajpath.2009.080785","article-title":"Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group","volume":"174","author":"Hildenbrand","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_36","first-page":"1918","article-title":"Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients","volume":"58","author":"Halamkova","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jso.21611","article-title":"Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer","volume":"102","author":"Renk","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"23099","DOI":"10.18632\/oncotarget.15485","article-title":"The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis","volume":"8","author":"Brungs","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1349-7006.2003.tb01350.x","article-title":"Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer","volume":"94","author":"Kaneko","year":"2003","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1747.2001.01241.x","article-title":"Cancer Cell Expression of Urokinase-Type Plasminogen Activator Receptor mRNA in Squamous Cell Carcinomas of the Skin","volume":"116","author":"Pyke","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/597927","article-title":"Transforming Growth Factor-Beta and Urokinase-Type Plasminogen Activator: Dangerous Partners in Tumorigenesis\u2014Implications in Skin Cancer","volume":"2013","author":"Santibanez","year":"2013","journal-title":"ISRN Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.1215","article-title":"Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)","volume":"92","author":"Borgfeldt","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_43","first-page":"1743","article-title":"Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer","volume":"7","author":"Konecny","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_44","first-page":"1843","article-title":"The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients","volume":"58","author":"Sier","year":"1998","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-014-0428-4","article-title":"uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies","volume":"16","author":"Duffy","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_46","first-page":"E329","article-title":"Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma","volume":"131","author":"Christensen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0046-8177(95)90276-7","article-title":"Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness","volume":"26","author":"Meling","year":"1995","journal-title":"Hum. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2007-1002607","article-title":"Components of the Plasminogen-Plasmin System in Human Tumor Cell Lines","volume":"17","author":"Kwaan","year":"1991","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3349-7","article-title":"Cleavage of the urokinase receptor (uPAR) on oral cancer cells: Regulation by transforming growth factor\u2014\u03b21 (TGF-\u03b21) and potential effects on migration and invasion","volume":"17","author":"Magnussen","year":"2017","journal-title":"BMC Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.3748\/wjg.15.5898","article-title":"Invasive front of colorectal cancer: Dynamic interface of pro-\/anti-tumor factors","volume":"15","author":"Zlobec","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-5347(17)38709-8","article-title":"Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype","volume":"142","author":"Gaylis","year":"1989","journal-title":"J. Urol."},{"key":"ref_52","first-page":"1787","article-title":"Localization of plasminogen activators in human colon cancer by immunoperoxidase staining","volume":"45","author":"Kohga","year":"1985","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/S0021-9258(19)50608-1","article-title":"Domain structure and interactions of recombinant urokinase-type plasminogen activator","volume":"267","author":"Novokhatny","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-4-431-66925-8_20","article-title":"Cathepsin B Efficiently Activets the Soluble and the Tumor Cell Receptor-Bound Form of the Proenzyme Urokinase-Type Plasminogen Activator (Pro-Upa)","volume":"266","author":"Kobayashi","year":"1992","journal-title":"Hemost. Circ."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0014-5793(92)80339-I","article-title":"Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L","volume":"297","author":"Goretzki","year":"1992","journal-title":"FEBS Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/S0021-9258(17)35674-0","article-title":"The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin","volume":"261","author":"Ichinose","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0167-4838(93)90203-4","article-title":"Characterization of the activation of pro-urokinase by thermolysin","volume":"1161","author":"Marcotte","year":"1993","journal-title":"Biochim. et Biophys. Acta (BBA)\u2014Protein Struct. Mol. Enzym."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1016\/S0021-9258(17)36896-5","article-title":"Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase)","volume":"269","author":"Stack","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1016\/S0021-9258(18)37940-7","article-title":"One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity","volume":"263","author":"Petersen","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12752","DOI":"10.1016\/S0021-9258(18)98963-5","article-title":"Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor","volume":"266","author":"Ellis","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0021-9258(18)61211-6","article-title":"The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases","volume":"262","author":"Appella","year":"1987","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shetty, S., and Idell, S. (2006). FIBRINOLYSIS|Plasminogen Activator and Plasmin. Encyclopedia of Respiratory Medicine, Academic Press.","DOI":"10.1016\/B0-12-370879-6\/00154-X"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kjaergaard, M., Hansen, L.V., Jacobsen, B., Gardsvoll, H., and Ploug, M. (2008). Structure and ligand interactions of the urokinase receptor (uPAR). Front. Biosci., 5441\u20135461.","DOI":"10.2741\/3092"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1074\/jbc.M610184200","article-title":"Mapping of the Vitronectin-binding Site on the Urokinase Receptor: Involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region","volume":"282","author":"Ploug","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nsmb.1404","article-title":"Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes","volume":"15","author":"Huai","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"32380","DOI":"10.1016\/S0021-9258(18)31646-6","article-title":"Identification of the urokinase receptor as an adhesion receptor for vitronectin","volume":"269","author":"Wei","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_68","first-page":"1684","article-title":"ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)","volume":"63","author":"Estrada","year":"2003","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1091\/mbc.12.4.863","article-title":"Urokinase Receptor and Fibronectin Regulate the ERKMAPK to p38MAPK Activity Ratios That Determine Carcinoma Cell Proliferation or Dormancy In Vivo","volume":"12","author":"Liu","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1083\/jcb.200612058","article-title":"uPAR-induced cell adhesion and migration: Vitronectin provides the key","volume":"177","author":"Madsen","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1158\/0008-5472.CAN-09-1636","article-title":"Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells","volume":"69","author":"Chen","year":"2009","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0033-1334483","article-title":"Plasminogen Receptors: The First Quarter Century","volume":"39","author":"Parmer","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0268-9499(08)80063-X","article-title":"Binding of plasminogen to corneal fibroblasts and their extracellular matrix. Evidence for a receptor in cell membranes","volume":"9","author":"Mirshahi","year":"1995","journal-title":"Fibrinolysis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1016\/S0021-9258(18)67293-X","article-title":"Binding of plasminogen to cultured human endothelial cells","volume":"261","author":"Hajjar","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/excr.1993.1238","article-title":"Binding and Activation of Plasminogen at the Surface of Human Keratinocytes","volume":"208","author":"Reinartz","year":"1993","journal-title":"Exp. Cell Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1055\/s-0038-1646019","article-title":"Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells","volume":"58","author":"Miles","year":"1987","journal-title":"Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1172\/JCI113814","article-title":"Binding of Lys-plasminogen to monocytes\/macrophages","volume":"82","author":"Silverstein","year":"1988","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/S0021-9258(18)89264-X","article-title":"Binding and activation of plasminogen on the platelet surface","volume":"260","author":"Miles","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"s294","DOI":"10.2741\/1044","article-title":"Plasminogen binding and cancer: Promises and pitfalls","volume":"8","author":"Ranson","year":"2003","journal-title":"Front. Biosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00001721-199210000-00012","article-title":"Plasminogen: A structural review","volume":"3","author":"Ponting","year":"1992","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.celrep.2012.02.012","article-title":"The X-ray Crystal Structure of Full-length Human Plasminogen","volume":"1","author":"Law","year":"2012","journal-title":"Cell Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11928","DOI":"10.1016\/S0021-9258(18)37875-X","article-title":"The cell-binding domains of plasminogen and their function in plasma","volume":"263","author":"Miles","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_83","first-page":"455","article-title":"Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for omega-aminocarboxylic acids","volume":"219","author":"Marti","year":"1994","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"18063","DOI":"10.1074\/jbc.M310462200","article-title":"Integrin \u03b1M\u03b22 Orchestrates and Accelerates Plasminogen Activation and Fibrinolysis by Neutrophils","volume":"279","author":"Pluskota","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0003-9861(91)90090-6","article-title":"Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding","volume":"286","author":"Stack","year":"1991","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/bcr1647","article-title":"Plasminogen binding and activation at the breast cancer cell surface: The integral role of urokinase activity","volume":"9","author":"Stillfried","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1016\/S0021-9258(18)98900-3","article-title":"Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin","volume":"266","author":"Hall","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"21229","DOI":"10.3390\/ijms151121229","article-title":"From Plasminogen to Plasmin: Role of Plasminogen Receptors in Human Cancer","volume":"15","author":"Didiasova","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.1998.261","article-title":"Increased plasminogen binding is associated with metastatic breast cancer cells: Differential expression of plasminogen binding proteins","volume":"77","author":"Ranson","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1006762425323","article-title":"Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro","volume":"18","author":"Balduyck","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","article-title":"Matrix metalloproteinases and tumor metastasis","volume":"25","author":"Deryugina","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/hq0701.093685","article-title":"Role of the Matrix Metalloproteinase and Plasminogen Activator\u2013Plasmin Systems in Angiogenesis","volume":"21","author":"Pepper","year":"2001","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_94","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhang, G., Miyake, M., Lawton, A., Goodison, S., and Rosser, C.J. (2014). Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-310"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z","article-title":"The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy","volume":"27","author":"Dunn","year":"2000","journal-title":"Mol. Carcinog."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1165\/rcmb.2006-0006OC","article-title":"Plasminogen-Mediated Activation and Release of Hepatocyte Growth Factor from Extracellular Matrix","volume":"35","author":"Matsuoka","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V79.5.1178.1178","article-title":"Regulation of Proteolytic Activity in Human Bone Marrow Stromal Cells by Basic Fibroblast Growth Factor, Interleukin-1, and Transforming Growth Factor \u03b2","volume":"79","author":"Hannocks","year":"1992","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/cam.22243","article-title":"VEGF-initiated angiogenesis and the uPA\/uPAR system","volume":"6","author":"Breuss","year":"2012","journal-title":"Cell Adhes. Migr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.20030361","article-title":"Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D","volume":"198","author":"McColl","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopha.2018.01.029","article-title":"Diversity and functional evolution of the plasminogen activator system","volume":"98","author":"Jaiswal","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.neo.7900229","article-title":"Insulin-Like Growth Factor-1 Inscribes a Gene Expression Profile for Angiogenic Factors and Cancer Progression in Breast Epithelial Cells","volume":"4","author":"Oh","year":"2002","journal-title":"Neoplasia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/gb-2006-7-5-216","article-title":"An overview of the serpin superfamily","volume":"7","author":"Law","year":"2006","journal-title":"Genome Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","article-title":"The plasminogen activator inhibitor-1 paradox in cancer: A mechanistic understanding","volume":"38","author":"Kubala","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6602743","article-title":"Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer","volume":"93","author":"Sakakibara","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_106","first-page":"4671","article-title":"Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue","volume":"54","author":"Pedersen","year":"1994","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/(SICI)1097-0215(19961220)69:6<475::AID-IJC10>3.0.CO;2-0","article-title":"Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors","volume":"69","author":"Berns","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0","article-title":"Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients","volume":"79","author":"Chambers","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/bjc.1997.435","article-title":"Plasminogen activator inhibitor type 2 in breast cancer","volume":"76","author":"Duggan","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0049-3848(92)90110-V","article-title":"Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues","volume":"65","author":"Nakamura","year":"1992","journal-title":"Thromb. Res."},{"key":"ref_111","first-page":"2094","article-title":"Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression","volume":"5","author":"Robert","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00268-006-0289-9","article-title":"High Expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma","volume":"31","author":"Smith","year":"2007","journal-title":"World J. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/bjc.1998.588","article-title":"Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: Association of decreased plasminogen activator inhibitor 2 with lymph node metastasis","volume":"78","author":"Yoshino","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_114","first-page":"599","article-title":"Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx","volume":"16","author":"Zhao","year":"2002","journal-title":"Lin Chuang Er Bi Yan Hou Ke Za Zhi = J. Clin. Otorhinolaryngol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ijc.1611","article-title":"High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer","volume":"97","author":"Nordengren","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_116","first-page":"4065","article-title":"Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer","volume":"54","author":"Ganesh","year":"1994","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc2400","article-title":"Revisiting the biological roles of PAI2 (SERPINB2) in cancer","volume":"8","author":"Croucher","year":"2008","journal-title":"Nat. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070767","article-title":"A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells","volume":"408","author":"Croucher","year":"2007","journal-title":"Biochem. J."},{"key":"ref_119","unstructured":"Takeuchi, Y., Nakao, A., Harada, A., Nonami, T., Fukatsu, T., and Takagi, H. (1993). Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: Immunohistochemical study. Am. J. Gastroenterol., 88."},{"key":"ref_120","first-page":"4935","article-title":"Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer","volume":"9","author":"Harvey","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_121","first-page":"1177271917715443","article-title":"Prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: Malignant versus stromal cells","volume":"12","author":"Baart","year":"2017","journal-title":"Biomark. Insights"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/onc.2017.63","article-title":"SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer","volume":"36","author":"Harris","year":"2017","journal-title":"Oncogene"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1440-1746.2004.03531.x","article-title":"Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction","volume":"20","author":"Nielsen","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/carcin\/bgz033","article-title":"High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma","volume":"40","author":"Loosen","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPA.0b013e31815750f0","article-title":"Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma","volume":"36","author":"Xue","year":"2008","journal-title":"Pancreas"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/BF01536670","article-title":"Elevated serum levels of tumor marker CA19-9 in acute cholangitis","volume":"33","author":"Albert","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"ref_127","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.20517\/2394-4722.2020.70","article-title":"Exploiting the relevance of CA 19-9 in pancreatic cancer","volume":"2020","author":"Salleh","year":"2020","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1038\/s41598-020-65720-8","article-title":"Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-57930-x","article-title":"CA19-9 for detecting recurrence of pancreatic cancer","volume":"10","author":"Azizian","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Kim, H., Kang, K.N., Shin, Y.S., Byun, Y., Han, Y., Kwon, W., Kim, C.W., and Jang, J.Y. (2020). Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Cancers, 12.","DOI":"10.3390\/cancers12061443"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1245\/s10434-018-6521-7","article-title":"CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time","volume":"25","author":"Rieser","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Hersz\u00e9nyi, L., Farinati, F., Cardin, R., Istv\u00e1n, G., Moln\u00e1r, L.D., Hritz, I., De Paoli, M., Plebani, M., and Tulassay, Z. (2008). Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-194"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pan.2011.12.011","article-title":"Invasive markers identified by gene expression profiling in pancreatic cancer","volume":"12","author":"Rogers","year":"2012","journal-title":"Pancreatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ijc.22487","article-title":"Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration","volume":"120","author":"Chen","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00365521.2020.1849383","article-title":"Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer","volume":"56","author":"Aronen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_137","first-page":"93","article-title":"The role of the tissue plasminogen activator as a prognostic and differentiation factor in patients with pancreatic cancer and chronic pancreatitis","volume":"67","author":"Baluka","year":"2016","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Sorio, C., Mafficini, A., Furlan, F., Barbi, S., Bonora, A., Brocco, G., Blasi, F., Talamini, G., Bassi, C., and Scarpa, A. (2011). Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-448"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4103\/0366-6999.247211","article-title":"Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma","volume":"131","author":"Liu","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1158\/1078-0432.CCR-06-2088","article-title":"Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis","volume":"13","author":"He","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1158\/1078-0432.CCR-13-2311","article-title":"FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System","volume":"20","author":"Huang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_142","first-page":"369","article-title":"Analysis of the invasion-metastasis mechanism in pancreatic cancer: Involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells","volume":"28","author":"Tan","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/cancers3021821","article-title":"Targeted Alpha Therapy Approach to the Management of Pancreatic Cancer","volume":"3","author":"Allen","year":"2011","journal-title":"Cancers"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/bi00220a034","article-title":"Role of cell-surface lysines in plasminogen binding to cells: Identification of .alpha.-enolase as a candidate plasminogen receptor","volume":"30","author":"Miles","year":"1991","journal-title":"Biochemistry"},{"key":"ref_145","first-page":"407","article-title":"The Role of an Enolase-Related Molecule in Plasminogen Binding to Cells","volume":"227","author":"Redlitz","year":"1995","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Almaguel, F.A., Sanchez, T.W., Ortiz-Hernandez, G.L., and Casiano, C.A. (2021). Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.614726"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.18632\/oncotarget.6798","article-title":"Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest","volume":"7","author":"Capello","year":"2015","journal-title":"Oncotarget"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","article-title":"Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation","volume":"27","author":"Lunt","year":"2011","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"11098","DOI":"10.18632\/oncotarget.3572","article-title":"Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells","volume":"6","author":"Principe","year":"2015","journal-title":"Oncotarget"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7150\/ijms.18736","article-title":"Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer","volume":"14","author":"Sun","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0385-8","article-title":"Alpha-enolase (ENO1) controls alpha v\/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis","volume":"10","author":"Principe","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/00006676-200208000-00021","article-title":"Expression of Integrin \u03b1V\u03b23 in Pancreatic Carcinoma: Relation to MMP-2 Activation and Lymph Node Metastasis","volume":"25","author":"Hosotani","year":"2002","journal-title":"Pancreas"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.117.5.1101","article-title":"Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen","volume":"117","author":"Leavesley","year":"1992","journal-title":"J. Cell Biol."},{"key":"ref_154","first-page":"79","article-title":"The relationship between bone metastasis from human breast cancer and integrin \u03b1v\u03b23 expression","volume":"25","author":"Takayama","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","article-title":"ERK and cell death: Mechanisms of ERK-induced cell death\u2014Apoptosis, autophagy and senescence","volume":"277","author":"Cagnol","year":"2010","journal-title":"FEBS J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3842198","DOI":"10.1155\/2018\/3842198","article-title":"ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance","volume":"2018","author":"Yin","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5208279","DOI":"10.1155\/2020\/5208279","article-title":"The Diagnostic Accuracy of Combined Enolase\/Cr, CA125, and CA19-9 in the Detection of Endometriosis","volume":"2020","author":"Rokhgireh","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_158","first-page":"505","article-title":"A preliminary study of serum marker alpha-enolase in the diagnosis of hepatocellular carcinoma","volume":"27","author":"Luo","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.2147\/CMAR.S182183","article-title":"Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients","volume":"10","author":"Zhu","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.24355","article-title":"An integrated humoral and cellular response is elicited in pancreatic cancer by \u03b1-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen","volume":"125","author":"Cappello","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2013.01.020","article-title":"Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer","volume":"144","author":"Cappello","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/pr100213b","article-title":"Circulating Autoantibodies to Phosphorylated \u03b1-Enolase are a Hallmark of Pancreatic Cancer","volume":"10","author":"Tomaino","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1742-4658.2011.08025.x","article-title":"\u03b1-enolase: A promising therapeutic and diagnostic tumor target","volume":"278","author":"Capello","year":"2011","journal-title":"FEBS J."},{"key":"ref_164","first-page":"5","article-title":"Annexin A2 and cancer: A systematic review","volume":"52","author":"Christensen","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12307-011-0064-9","article-title":"The Role of Annexin A2 in Tumorigenesis and Cancer Progression","volume":"4","author":"Lokman","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.2174\/138161207782794167","article-title":"The role of annexin II in angiogenesis and tumor progression: A potential therapeutic target","volume":"13","author":"Sharma","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1182\/blood-2011-06-334672","article-title":"The role of the annexin A2 heterotetramer in vascular fibrinolysis","volume":"118","author":"Madureira","year":"2011","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/bi981713l","article-title":"The p11 Subunit of the Annexin II Tetramer Plays a Key Role in the Stimulation of t-PA-Dependent Plasminogen Activation","volume":"37","author":"Kassam","year":"1998","journal-title":"Biochemistry"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.3390\/ijms14036259","article-title":"Annexin A2 Heterotetramer: Structure and Function","volume":"14","author":"Bharadwaj","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1074\/jbc.273.8.4790","article-title":"The Role of Annexin II Tetramer in the Activation of Plasminogen","volume":"273","author":"Kassam","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcb.21835","article-title":"Annexin II\/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer","volume":"105","author":"Shiozawa","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1245\/s10434-008-0061-5","article-title":"Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy","volume":"15","author":"Takano","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"106405","DOI":"10.18632\/oncotarget.22433","article-title":"Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer","volume":"8","author":"Murphy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1093\/carcin\/14.12.2575","article-title":"Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers","volume":"14","author":"Vishwanatha","year":"1993","journal-title":"Carcinogenesis"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/gut.2003.026831","article-title":"Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro","volume":"53","author":"Hurtado","year":"2004","journal-title":"Gut"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.onc.1201564","article-title":"The plasminogen activator system in pancreas cancer: Role of t-PA in the invasive potential in vitro","volume":"16","author":"Paciucci","year":"1998","journal-title":"Oncogene"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Zheng, L., Foley, K., Huang, L., Leubner, A., Mo, G., Olino, K., Edil, B.H., Mizuma, M., Sharma, R., and Le, D.T. (2011). Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019390"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bjc.6605289","article-title":"S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility","volume":"101","author":"Nedjadi","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/pr800890j","article-title":"Analysis of the Pancreatic Tumor Progression by a Quantitative Proteomic Approach and Immunhistochemical Validation","volume":"8","author":"Sitek","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4174\/astr.2018.94.5.247","article-title":"Clinical significance of pancreatic intraepithelial neoplasia in resectable pancreatic cancer on survivals","volume":"94","author":"Yu","year":"2018","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/1878-0261.12356","article-title":"S100A10, a novel biomarker in pancreatic ductal adenocarcinoma","volume":"12","author":"Bydoun","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1111\/jcmm.16343","article-title":"Prognostic values and immune suppression of the S100A family in pancreatic cancer","volume":"25","author":"Zhuang","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08769-6","article-title":"Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/jco.2013.31.4_suppl.194","article-title":"The clinical significance of S100A10 in pancreatic cancer","volume":"31","author":"Yamamoto","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1083\/jcb.101.5.1826","article-title":"Pair formation and promiscuity of cytokeratins: Formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides","volume":"101","author":"Hatzfeld","year":"1985","journal-title":"J. Cell Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.MP.0000067683.84284.66","article-title":"Expression of Mucins and Cytokeratins in Primary Carcinomas of the Digestive System","volume":"16","author":"Lee","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"d1403","DOI":"10.2741\/Gonias","article-title":"Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells","volume":"6","author":"Steven","year":"2001","journal-title":"Front. Biosci."},{"key":"ref_188","first-page":"845","article-title":"Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18","volume":"17","author":"Kralovich","year":"1998","journal-title":"Protein J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbrc.2006.02.139","article-title":"CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck","volume":"343","author":"Gires","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_190","first-page":"871","article-title":"Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis","volume":"4","author":"Xu","year":"1995","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/sj.bjc.6605313","article-title":"Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus","volume":"101","author":"Makino","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-6-10","article-title":"Cytokeratin 8\/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity","volume":"6","author":"Fillies","year":"2006","journal-title":"BMC Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-5002(02)00109-5","article-title":"Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients","volume":"38","author":"Fukunaga","year":"2002","journal-title":"Lung Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000132572","article-title":"Full-Length Cytokeratin 8 Is Released and Circulates in Patients with Non-Small Cell Lung Cancer","volume":"29","author":"Ishii","year":"2008","journal-title":"Tumor Biol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"25684","DOI":"10.1074\/jbc.271.41.25684","article-title":"Cell-surface Cytokeratin 8 Is the Major Plasminogen Receptor on Breast Cancer Cells and Is Required for the Accelerated Activation of Cell-associated Plasminogen by Tissue-type Plasminogen Activator","volume":"271","author":"Hembrough","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1242\/jcs.108.3.1071","article-title":"A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines","volume":"108","author":"Hembrough","year":"1995","journal-title":"J. Cell Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00428-007-0570-9","article-title":"Molecular characterisation of breast cancer patients at high and low recurrence risk","volume":"452","author":"Bonin","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Iyer, S.V., Dange, P.P., Alam, H., Sawant, S.S., Ingle, A.D., Borges, A.M., Shirsat, N.V., Dalal, S.N., and Vaidya, M.M. (2013). Understanding the Role of Keratins 8 and 18 in Neoplastic Potential of Breast Cancer Derived Cell Lines. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053532"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI5343","article-title":"Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8","volume":"103","author":"Casanova","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00109-006-0096-7","article-title":"Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer","volume":"84","author":"Treiber","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16711-w","article-title":"Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer","volume":"11","author":"Lin","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_202","first-page":"297","article-title":"A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker","volume":"2020","author":"Scott","year":"2021","journal-title":"Biocomputing"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"DNA hypomethylation in cancer cells","volume":"1","author":"Ehrlich","year":"2009","journal-title":"Epigenomics"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/301089a0","article-title":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","volume":"301","author":"Feinberg","year":"1983","journal-title":"Nature"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: An accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"607209","DOI":"10.3389\/fcell.2020.607209","article-title":"Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4049\/jimmunol.1102073","article-title":"\u03b1-Enolase Expressed on the Surfaces of Monocytes and Macrophages Induces Robust Synovial Inflammation in Rheumatoid Arthritis","volume":"189","author":"Bae","year":"2012","journal-title":"J. Immunol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2162-3619-2-12","article-title":"Three are better than one: Plasminogen receptors as cancer theranostic targets","volume":"2","author":"Ceruti","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood-2010-01-264754","article-title":"S100A10 regulates plasminogen-dependent macrophage invasion","volume":"116","author":"Surette","year":"2010","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"593706","DOI":"10.3389\/fonc.2020.593706","article-title":"Enolase 1 Correlated with Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis","volume":"10","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood-2008-11-188938","article-title":"Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation","volume":"115","author":"Andronicos","year":"2010","journal-title":"Blood"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood.V118.21.853.853","article-title":"The Novel Plasminogen Receptor, Plg-RKT, and Breast Cancer Progression","volume":"118","author":"Miles","year":"2011","journal-title":"Blood"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"9463","DOI":"10.1021\/bi060756w","article-title":"Identification of Histone H2B as a Regulated Plasminogen Receptor","volume":"45","author":"Herren","year":"2006","journal-title":"Biochemistry"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood-2007-03-079392","article-title":"Histone H2B as a functionally important plasminogen receptor on macrophages","volume":"110","author":"Das","year":"2007","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Garcia-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., and Acedo, P. (2021). The State-of-the-Art of Phase II\/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040566"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/jco.2010.28.15_suppl.4060","article-title":"Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer","volume":"28","author":"Heinemann","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/1381612033454649","article-title":"Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator","volume":"9","author":"Rockway","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2174\/138620709789824727","article-title":"Challenges for drug discovery\u2014A case study of urokinase receptor inhibition","volume":"12","author":"Chen","year":"2009","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Salamouni, N.S.E., Buckley, B.J., Ranson, M., Kelso, M.J., and Yu, H. (2022). Urokinase plasminogen activator as an anti-metastasis target: Inhibitor design principles, recent amiloride derivatives, and issues with human\/mouse species selectivity. Biophys. Rev., 1\u201325.","DOI":"10.31219\/osf.io\/3z5m4"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543776.13.6.773","article-title":"Small molecule inhibitors of urokinase-type plasminogen activator","volume":"13","author":"Rockway","year":"2003","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0969-2126(01)00203-9","article-title":"The crystal structure of the catalytic domain of human urokinase-type plasminogen activator","volume":"3","author":"Spraggon","year":"1995","journal-title":"Structure"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0969-2126(00)00136-2","article-title":"Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite","volume":"8","author":"Nienaber","year":"2000","journal-title":"Structure"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"33613","DOI":"10.1074\/jbc.M314151200","article-title":"Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents","volume":"279","author":"Schweinitz","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"625176","DOI":"10.1155\/2014\/625176","article-title":"Application of Molecular Modeling to Urokinase Inhibitors Development","volume":"2014","author":"Sulimov","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","article-title":"6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer","volume":"61","author":"Buckley","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"126753","DOI":"10.1016\/j.bmcl.2019.126753","article-title":"6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease","volume":"29","author":"Buckley","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Buckley, B.J., Kumar, A., Aboelela, A., Bujaroski, R.S., Li, X., Majed, H., Fliegel, L., Ranson, M., and Kelso, M.J. (2021). Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA\/NHE1 Active and Single Target-Selective Inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062999"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"116116","DOI":"10.1016\/j.bmc.2021.116116","article-title":"Systematic evaluation of structure\u2013property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride","volume":"37","author":"Buckley","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med., 365, 395\u2013409.","DOI":"10.1056\/NEJMoa1102873"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1309086","article-title":"Adenoma Detection Rate and Risk of Colorectal Cancer and Death","volume":"370","author":"Corley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","article-title":"Prevention and early detection of prostate cancer","volume":"15","author":"Cuzick","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"Scholten","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/SLA.0b013e31825ffbfb","article-title":"Screening for pancreatic cancer: Why, how, and who?","volume":"257","author":"Poruk","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","article-title":"Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"62","author":"Hugosson","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1148\/radiol.11110469","article-title":"Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades","volume":"260","author":"Vitak","year":"2011","journal-title":"Radiology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3748\/wjg.v20.i24.7864","article-title":"Imaging diagnosis of pancreatic cancer: A state-of-the-art review","volume":"20","author":"Lee","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/gutjnl-2014-308008","article-title":"A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals","volume":"65","author":"Harinck","year":"2016","journal-title":"Gut"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early Detection of Pancreatic Cancer: Opportunities and Challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5946\/ce.2012.45.2.115","article-title":"Introduction; Value of Endoscopic Ultrasound-Guided Fine Needle Aspiration","volume":"45","author":"Kim","year":"2012","journal-title":"Clin. Endosc."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000496507","article-title":"Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues","volume":"37","author":"Narkhede","year":"2019","journal-title":"Dig. Dis."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MPA.0000000000001075","article-title":"Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer","volume":"47","author":"Tummers","year":"2018","journal-title":"Pancreas"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"73912","DOI":"10.18632\/oncotarget.12528","article-title":"Antibody-based PET of uPA\/uPAR signaling with broad applicability for cancer imaging","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.7150\/thno.43589","article-title":"Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma","volume":"10","author":"Kryza","year":"2020","journal-title":"Theranostics"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1158\/1078-0432.CCR-20-0268","article-title":"Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer","volume":"26","author":"Moroz","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1158\/0008-5472.CAN-10-0220","article-title":"CUB Domain\u2013Containing Protein 1, a Prognostic Factor for Human Pancreatic Cancers, Promotes Cell Migration and Extracellular Matrix Degradation","volume":"70","author":"Miyazawa","year":"2010","journal-title":"Cancer Res."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-20-2978","article-title":"The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention","volume":"81","author":"Khan","year":"2021","journal-title":"Cancer Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41589-021-00783-w","article-title":"Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1","volume":"17","author":"Kryza","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2967\/jnumed.110.083386","article-title":"Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion","volume":"53","author":"Persson","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.12956","article-title":"First-in-human uPAR PET: Imaging of Cancer Aggressiveness","volume":"5","author":"Persson","year":"2015","journal-title":"Theranostics"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/cpf.12037","article-title":"Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: Potential clinical applications","volume":"33","author":"Persson","year":"2013","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nucmedbio.2013.03.001","article-title":"First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts","volume":"40","author":"Persson","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.116.178970","article-title":"Safety, Dosimetry, and Tumor Detection Ability of 68 Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging","volume":"58","author":"Skovgaard","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0010","article-title":"Near-infrared fluorophores for biomedical imaging","volume":"1","author":"Hong","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.18632\/oncotarget.27220","article-title":"Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: Comparison with traditional white light surgery","volume":"10","author":"Juhl","year":"2019","journal-title":"Oncotarget"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:15Z","timestamp":1760133795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":254,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biom12020152"],"URL":"https:\/\/doi.org\/10.3390\/biom12020152","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}